Metabolomic Insights for Neurology: Alzheimer’s Disease

Alzheimer’s disease is a progressive neurodegenerative disorder with no cure and limited treatment options. As the disease advances, widespread metabolic disruption occurs, driving cognitive decline and complicating therapeutic development. By looking beyond individual pathways and examine the full metabolic landscape, new insights can emerge. Panome Bio’s Next-Generation Metabolomics provides the functional and biochemical map needed to uncover the upstream drivers and precise mechanisms behind these disorders.

Researchers are using metabolomics to better understand Alzheimer’s disease and its progression. Untargeted metabolomics has many advantages for studying neurological diseases:

• Broad and Deep Coverage: Polar, lipid, and intermediate metabolites detected all in one assay.
• High-Resolution Data: Detects low-abundance metabolites and structural isomers.
• Identification Confidence: Result are scientifically defensible and translationally ready.
• Connected Biology: Links metabolism to proteins and signaling, providing a complete picture of disease.
• Proven Workflow: Deep metabolic profiling can redefine understanding of complex neurological disorders, as demonstrated in our Alzheimer’s disease study.

In a case study, Panome Bio’s Next Generation Metabolomics® platform uncovered broad metabolic changes, shedding light on the biological consequences of Alzheimer’s Disease and pointing toward new opportunities and intervention.

Serum samples were obtained from patients diagnosed with Alzheimer’s disease and age- and sex-matched healthy controls, with the patient group representing moderate disease stages. Untargeted metabolomics profiling was performed using Panome Bio’s universal Next-Generation Metabolomics platform, which comprehensively profiles lipid, polar, and intermediate compounds. The results are remarkable:

Significantly Altered Metabolites highlights the complex biochemical impact of Alzheimer’s disease

• Alzheimer’s samples showed clear metabolic shifts.
• Elevated metabolites: related to energy, lipid and glycoproteins.
• Reduced metabolites: nucleotides, bile acids, cholesterol esters, and vitamins.
• Indicates widespread disruptions in energy use, lipid balance, and essential nutrient metabolism.

Pioneer the Path Forward in Neurodegeneration:

Metabolomics reveals the functional endpoint of disease. To understand what drives these metabolic changes and the underlying mechanisms in Alzheimer’s research Panome Bio offers:

• Design Targeted Experiments: Use metabolic signatures to guide preclinical studies.
• Discovery & Targeted Proteomics: Monitor enzyme activity, pathway flux, and protein changes (e.g., APOE, inflammatory proteins).
• Global Phosphoproteomics: Map post-translational modifications to understand signaling and Tau pathology.
• Transcriptomics: Link gene expression to protein and metabolite changes, connecting AD risk genes to functional outcomes.
• Integrated Multi-Omics: Integrate all Omics data to validate and expand disease understanding.